Freedberg Daniel E, Messina Megan, Lynch Elissa, Tess Monika, Miracle Elizabeth, Chong David H, Wahab Romina, Abrams Julian A, Wang Harris H, Munck Christian
Division of Digestive and Liver Diseases, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY.
Department of Food and Nutrition, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY.
Crit Care Explor. 2020 Jun 11;2(6):e0135. doi: 10.1097/CCE.0000000000000135. eCollection 2020 Jun.
Dietary fiber increases the abundance of bacteria that metabolize fiber into short-chain fatty acids and confers resistance against gut colonization with multidrug-resistant bacteria. This pilot trial estimated the effect of fiber on gut short-chain fatty acid-producing bacteria in the ICU.
Randomized, controlled, open label trial.
Medical ICU.
Twenty ICU adults receiving broad-spectrum IV antibiotics for sepsis.
1:1 randomization to enteral nutrition with mixed soy- and oat-derived fiber (14.3 g fiber/L) versus calorie- and micronutrient-identical enteral nutrition with 0 g/L fiber.
Rectal swabs and whole stools were collected at baseline and on study Days 3, 7, 14, and 30. The primary outcome was within-individual change in the cumulative relative abundance of short-chain fatty acid-producing taxa from baseline to Day 3 based on 16S sequencing of rectal swabs. The secondary outcome was Day 3 cumulative short-chain fatty acid levels based on mass spectrometry of whole stools. Analyses were all intent to treat.
By Day 3, the fiber group received a median of 32.1 g fiber cumulatively (interquartile range, 17.6-54.6) versus 0 g fiber (interquartile range, 0-4.0) in the no fiber group. The median within-individual change in short-chain fatty acid producer relative abundance from baseline to Day 3 was +61% (interquartile range -51 to +1,688) in the fiber group versus -46% (interquartile range, -78 to +13) in the no fiber group ( = 0.28). Whole stool short-chain fatty acid levels on Day 3 were a median of 707 μg short-chain fatty acids/g stool (interquartile range, 190-7,265) in the fiber group versus 118 μg short-chain fatty acids/g stool (interquartile range, 22-1,195) in the no fiber group ( = 0.16).
Enteral fiber was associated with nonsignificant trends toward increased relative abundance of short-chain fatty acid-producing bacteria and increased short-chain fatty acid levels among ICU patients receiving broad-spectrum IV antibiotics. Larger studies should be undertaken and our results can be used for effect size estimates.
膳食纤维可增加将纤维代谢为短链脂肪酸的细菌数量,并赋予对多重耐药菌肠道定植的抵抗力。这项初步试验评估了纤维对重症监护病房(ICU)中肠道短链脂肪酸产生菌的影响。
随机、对照、开放标签试验。
内科重症监护病房。
20名因败血症接受广谱静脉抗生素治疗的成年ICU患者。
按1:1随机分组,分别接受含大豆和燕麦混合纤维的肠内营养(14.3克纤维/升)与热量和微量营养素相同但纤维含量为0克/升的肠内营养。
在基线以及研究第3、7、14和30天收集直肠拭子和全粪便。主要结局是根据直肠拭子的16S测序,从基线到第3天个体内短链脂肪酸产生类群的累积相对丰度变化。次要结局是根据全粪便质谱分析得出的第3天短链脂肪酸累积水平。所有分析均采用意向性分析。
到第3天,纤维组累积摄入纤维的中位数为32.1克(四分位间距,17.6 - 54.6),而无纤维组为0克(四分位间距,0 - 4.0)。纤维组从基线到第3天短链脂肪酸产生菌相对丰度的个体内中位数变化为 +61%(四分位间距,-51至 +1,688),无纤维组为 -46%(四分位间距,-78至 +13)(P = 0.28)。纤维组第3天全粪便短链脂肪酸水平的中位数为707微克短链脂肪酸/克粪便(四分位间距,190 - 7,265),无纤维组为118微克短链脂肪酸/克粪便(四分位间距,22 - 1,195)(P = 0.16)。
在接受广谱静脉抗生素治疗的ICU患者中,肠内纤维与短链脂肪酸产生菌相对丰度增加及短链脂肪酸水平升高的非显著趋势相关。应开展更大规模的研究,我们的结果可用于效应量估计。